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Abstract
A new water-based topical formulation is presented that aims at providing good penetration
properties for both lipophilic and hydrophilic drugs with as small a disturbance of the skin barrier
function as possible. The formulation contains dispersed lipids in a ratio resembling that of human
skin. The capacity to deliver is addressed in this first study while the mild effect on skin will be
presented later. Three variations of the lipid formulation were investigated by use of pigskin in vitro
diffusion cell. The hydrophilic 5(6)-carboxyfluorescein (CF) and the lipophilic acridine orange 10-
nonyl bromide (AO) were used as model drug substances. The results showed that the delivery
properties of the new formulation exceeded that of the references (vaseline and xanthan gum gel).
The effect was largest for lipophilic AO where all lipid matrix formulations were superior in amount
detected in the skin. The results for the hydrophilic CF were also promising. Especially efficient was
the lipid formulation containing the non-ionic adjuvants tetra ethylene glycol monododecyl ether
and polyoxyethylene 23 dodecyl ether. The additional in vivo study suggests that the used in vitro
model has qualitative bearing on relevant in vivo situations.
Introduction
The human skin, and especially epidermis, constitutes an
efficient barrier for foreign substances to penetrate the
skin. The ability to circumvent this barrier depends on the
properties of the foreign substance as well as the status of
different parts of the skin. For instance it has been
reported that lipophilic small molecules in general pene-
trate deeper than do larger hydrophilic ones [1,2]. The
thickness of the epidermis varies but is in the order of a
few hundred µm and consists of stratum corneum, stra-
tum granulosum, stratum spinosum and the stratum
basale. The stratum corneum gives the main contribution
to the barrier function against diffusion across the skin
[3]. The stratum corneum consists of corneocytes sur-
rounded by lipids and is commonly described by the
brick-and-mortar model [4,5]. Stratum corneum lipids in
general are long-chained and have high chain-melting
temperatures [6]. For the purpose of drug delivery via top-
ical administration it is required that a large enough
amount of drug should successfully penetrate the SC and
reach the target in order to obtain therapeutic effects. In
order to facilitate penetration so called enhancers are
often used together with the drug. Several enhancers, such
as ethanol, dimethylsulfoxide and terpenes, have been
shown successful in their task to promote penetration [7-
9]. A common side effect of these enhancers is on the
other hand that the barrier function of SC is disturbed for
long periods of time after skin application [7,10]. This
results in a more sensitive skin and irritancy. In addition,
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if the disturbance of the barrier function has a long time
span the risk of unwanted uptake increases.
The choice of formulation for the drug is also important
in order to obtain a suitable release profile, solubility/dis-
persability and stability of the drug. There are numerous
examples where a suitable carrier system dramatically
improves drug efficacy without the effect being solely pen-
etration enhancement as such [3]. The most functional
formulation should therefore be able to solubilise both
hydrophilic and lipophilic substances and at the same
time increase uptake efficiently without causing notable
damage to the skin. In this context, a prerequisite for the
present study was that several studies showed that the
presence of lipid materials that resembles the ratio of
human skin are beneficial for barrier recovery [10-13].
The present study contains a topical formulation that con-
sists of dispersed lipids with a composition that resembles
that of human stratum corneum. The lipid part consists of
fatty acids, cholesterol, phospholipids and ceramide. The
phospholipids are a substitute for a large part of the cera-
mides due to commercial reasons. The formulation is
formed by mixing three different fractions that are proc-
essed individually. A mixer is used to form a disperse lipid
phase and a sonicator to form an ultra-fine disperse lipid
phase. The latter process results in vesicles, a type of carrier
that is frequently studied in dermatology and has been
shown to increase the delivered amount of drug both for
lipophilic and hydrophilic drugs [3,6,14]. The two dis-
persed lipid phases are mixed together and a third phase,
the polymer phase, that contributes to viscosity and tex-
ture is added. Consumer compliance has been important
for the development of the formulation and the idea is to
combine small submicron vesicles beneficial for delivery
with larger dispersed structures that contributes to the
lubricating feeling on skin. In the present study the focus
is on penetration properties of the formulation.
The in vitro penetration on pig-skin of three different ver-
sions of the formulation were investigated and compared
with appropriate references. Both hydrophilic and hydro-
phobic model actives were used. Any evidence of a rapid
repair of the barrier function is the focus of a coming
study and will not specifically be addressed here.
Materials and methods
Materials
Epikuron 200SH was obtained from Degussa BioActives
(Hamburg, Germany). Cholesterol, triethanol amine and
phenonip (preservative) were obtained from Vendico
Chemical (Malmö, Sweden). SK-influx was obtained from
Goldschmidt Personal Care, Essen, Germany. Mevalonic
acid, propylene glycol, glycerol, polyvinylpyrrolidone,
xanthan gum, tetraethylene glycol monododecyl ether,
polyoxyethylene 23 dodecyl ether and 5(6)-carboxyfluo-
rescein (CF) were obtained from Sigma. HEPES was
obtained from Acros Organics. Acridine orange 10-nonyl
bromide (AO) was obtained from Fluka. Sodium hydrox-
ide and sodium chloride were obtained from Merck. Vase-
line (petrolatum gel) was purchased from Apoteksbolaget
AB, Stockholm, Sweden. The water used was double dis-
tilled, deionised and filtered with a Milli-Q system.
Manufacturing
Typically ten grams of total formulation was prepared
containing: 7.95 g water, 0.35 g Epikuron 200SH, 0.15 g
cholesterol, 0.15 g palmitic acid, 0.2 g SK-influx, 0.4 g pro-
pylene glycol, 0.3 g glycerol, 0.2 g polyvinyl pyrrolidone,
0.2 g xanthan gum, 0.05 g triethanol amine, 0.04 g Phe-
nonip, 0.01 g mevalonic acid. The pH was adjusted to
7.4–7.6 by use of NaOH. The concentrations used for the
model drugs were 60 mM for the lipophilic AO and 30
mM for the hydrophilic CF. In case any other additives
were added (e.g. adjuvants) the amount of water was
reduced so that all other components were kept at the
level described above.
Dispersed lipid phase
Half of the lipid material (including cholesterol) was
added to a third of the total water. Half of the triethanol
amine, half of the phenonip and half of the model active
were also added unless otherwise stated. The fraction was
heated to 70°C whilst stirring for approximately 30 min-
utes. The fraction was processed with an Ultra Turrax
homogeniser for one minute at a speed of 9500 rpm. After
this the fraction was let to cool down. The process results
in a homogeneous lipid dispersion.
Amount of CF detected in stratum corneum, total skin and  the receiver compartment Figure 1
Amount of CF detected in stratum corneum, total skin and 
the receiver compartment. Errors are standard errors of 
mean.Lipids in Health and Disease 2006, 5:12 http://www.lipidworld.com/content/5/1/12
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Ultra-fine dispersed lipid phase
The ultra-fine dispersed phase has the same chemical
composition as the disperse lipid phase. This fraction was
also heated to 70°C whilst stirring for approximately 30
minutes. The fraction was sonicated by use of a Soniprep
150, (Sanyo Gallencamp Plc) for 30 minutes. After this
the fraction was let to cool down. The process creates a
vesicle dispersion.
Polymer phase
The propylene glycol, glycerol, polyvinyl pyrrolidone and
xanthan gum was added to a third of the total water. The
fraction was heated to 70°C whilst stirring for approxi-
mately 30 minutes after which the fraction was left to cool
down.
Mixing
The three phases were added in a beaker and the mix was
stirred manually for 5 minutes.
Reference formulations
The xanthan gum gel was manufactured by heating the
appropriate amount of water to 70°C and adding thereaf-
ter adding 2% xanthan gum. The gel was stirred until no
lumps were visible. The reference for Acridine Orange was
Vaseline (a petrolatum gel) mixed with the appropriate
amounts of AO. The petrolatum gel was stirred for at least
one hour and it was confirmed that no AO crystals were
present prior to usage.
Characterisation
Dispersed lipid phase
After processing, the dispersed lipid phase was investi-
gated by means of light microscopy. The structures present
are large (from a few microns up to hundreds of microns)
and therefore the actual distribution was not considered
to be crucial for penetration efficacy. No lumps were
present in the formulation after processing. No difference
between the formulations was observed regarding the dis-
persed lipid phase.
Ultra-fine dispersed phase
The properties of the small vesicle carriers were expected
to have impact on the penetration profile. Therefore focus
was set on characterisation of the vesicles in the ultra-fine
dispersed phase. An autosizer (Malvern Zetasizer 1000HS,
Malvern Instruments Ltd, Malvern, UK) was used to study
the size distribution of the vesicles in the various vesicle
fractions and a zetasizer (Malvern Zetasizer 2000, Malvern
Instruments Ltd, Malvern, UK) was used to study the zeta
potential. For proper determination dilution was neces-
sary. The dilution may to a small extent result in reduced
aggregation but is not expected to reduce the size of the
primary structures (the vesicles). The adjuvants (dodecyl
ethers) are expected to be more depleted from the mem-
brane upon dilution but not to any extent that dramati-
cally effects the size distribution. For the size distribution
water was used and for the zeta-potential measurements
10 mM NaCl was used. The investigated parameters are
shown in Table I and II in the Results section. For the par-
ticle diameter the presented value is an average of three
averages obtained from ten single runs. The error pre-
sented is the standard error of the means. The zeta-poten-
tial is an average of five single runs. The error presented is
the standard deviation.
Penetration in vitro model
Diffusion cell
Skin was mounted on diffusion cells (Laboratory Glass
Apparatus Inc., CA, USA), with a surface area of 0.67 cm2
and a receiver capacity of 3 ml, stratum corneum facing
upwards.
Pig ear skin from pigham pigs, 7–8 months old, was used.
The ears were obtained from Swedish Meat (Uppsala,
Sweden) approximately two hours after slaughter and pre-
pared the same day. Skin was removed with a scalpel. The
appropriate thickness (640 µm) was obtained by use of a
manual dermatome (Padgett Dermatome, Padgett Instru-
ments Inc., Kansas City). An amount of 100 µl of the for-
mulation was applied to the skin and carefully spread to
cover the entire surface area. The formulations were
Table 1: Characterisation data of the ultra-fine phase for 5 (6)-Carboxyfluorescein
CF-A CF-B CF-C
Particle diameter/nm 276 ± 2 494 ± 20 975 ± 196
Zeta-potential/mV -39.5 ± 0.5 -41.1 ± 0.7 -33.0 ± 2.4
Table 2: Characterisation data of the vesicle phase for Acridine orange 10-nonyl bromide
AO-A AO-B AO-C
Particle diameter/nm 344 ± 8 1730 ± 994 1395 ± 194
Zeta-potential/mV -36.0 ± 0.8 -35.3 ± 0.9 -30.5 ± 0.9Lipids in Health and Disease 2006, 5:12 http://www.lipidworld.com/content/5/1/12
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applied within a week from the day of formulation.
Because of the high viscosity of the formulations the exact
amount was determined by weighing after application.
For each formulation three experiments were performed,
using skin patches from different animals. The receiver
compartment was continuously rinsed with 25 mM
HEPES buffer containing 133 mM NaCl (isotonic condi-
tions). The pH of the buffer was set to 7.4 by addition of
1 M NaOH and before use the buffer was placed in an
ultrasound bath for a few minutes to remove air bubbles.
When connecting the buffer solution to the receiver com-
partment care was exercised to ensure that no air bubbles
appeared on the dermal side of the skin or elsewhere in
the receiver compartment. The receiver solution was con-
tinuously stirred using a small magnet and the tempera-
ture was maintained at 37°C throughout the experiment
by coupling a water bath (HETO, Denmark) to the cells.
The experiments were carried out for 24 hours under non-
occluded conditions and fractions were collected from the
receiver. The flow rate of the receiver solution was set to
1–2 ml/h and fractions were collected every 90 minutes
throughout the experiment. After 24 hours the flow
through the receiver compartment was stopped and the
donor compartment was rinsed. First rinsing was per-
formed with 10 ml HEPES buffer followed by 20 ml meth-
anol. In cases where the formulation contained 10-nonyl
bromide acridine orange the first rinsing step was
excluded since the probe is not soluble in HEPES buffer.
Tape stripping procedure
The skin patch was put up on a board, the remaining dried
formulation was removed and placed in HEPES buffer
and the skin was stripped. The stripping was carried out
using adhesive tape (Scotch magic tape, 3 M) by covering
the area of the skin that had been in contact with the for-
mulation with a piece of tape, 1.9 cm wide and 4 cm long.
15 strippings were performed to ensure that the stratum
corneum was removed [15]. The first two tape strips were
used to get rid of excess formulation on the skin. Strip 3–
5 represent the upper stratum corneum, tape strip 6–10 rep-
resent the middle stratum corneum and the final 5 repre-
sent the lower stratum corneum. The strips were placed into
5 ml HEPES buffer or 5 ml methanol depending on the
solubility of the probe. The remaining skin was placed in
HEPES buffer for at least 48 hours and after that in meth-
anol for at least 24 hours. These solutions are referred to
as the extraction fractions. In cases where the formulation
contained acridine orange 10-nonyl bromide the skin was
only placed in methanol for at least 24 hours.
Fraction analysis
The collected fractions were analysed by use of a spec-
trofluorimeter (FluoroMax-2, Instruments S.A, Inc.). The
wavelengths of analysis were 490 nm (excitation) and 513
nm (emission) for CF in HEPES and 490 nm (excitation)
and 517 nm (emission) for AO in methanol. Special care
was taken in order for the fractions containing CF to be in
a linear concentration to intensity region [16]. At the used
wavelengths no interference of naturally occurring fluo-
rescent components from skin could be detected. The data
presented in Figures 1, 2, 3 are from three different runs
for each formulation and each sample was analysed in
triplicate. The errors shown are the standard errors of the
means.
In vivo penetration experiments
Tracer amounts of the fluorescent dye NDB C6-ceramide
were added to the total lipid formulation and to the con-
trol (petrolatum). The total lipid formulation or control
was applied to hairless mice epidermis. Skin biopsies,
from three animals in each experimental group were taken
two hours after application for fluorescence microscopy
(Zeiss Axioplan 2).
Results and discussion
Skin penetration in vitro
The penetration performances of three different variations
of the formulation were investigated by use of a pig ear
skin diffusion cell. The variations were:
A) Formulation with 50% model active in dispersed lipid
phase and 50% in ultra-fine dispersed lipid phase.
B) Formulation with all model active in untra-fine dis-
persed lipid phase.
C) Formulation containing the non-ionic adjuvants, tetra-
ethylene glycol monododecyl ether and polyoxyethylene
23 glycol monododecyl ether, with 50% model active in
Amount of AO detected in stratum corneum and total skin Figure 2
Amount of AO detected in stratum corneum and total skin. 
Errors are standard errors of mean.Lipids in Health and Disease 2006, 5:12 http://www.lipidworld.com/content/5/1/12
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dispersed lipid phase and 50% in ultra-fine dispersed
lipid phase.
The penetration of the formulations were compared with
appropriate references. Pigskin was chosen since its stra-
tum corneum structure resembles human stratum cor-
neum more than does mouse skin [17].
Firstly, the permeation of the hydrophilic CF was investi-
gated. The results for CF (Fig. 1) show the amount
detected in the stratum corneum, the total amount
detected in all skin fractions and the amount detected in
the receiver.
The amount detected in stratum corneum is similar for all
four formulations except for CF C that contains polyox-
yethylene alkyl ethers. The non-ionic surfactants are
expected to work in a similar fashion as do other non-
ionic surfactants, such as Tween 20 or Synperonics [7].
The larger amount found in the stratum corneum for CF C
shows that the adjuvants are successful. This is empha-
sised by the fact that even though the total amount deliv-
ered to skin is similar for CF-B and CF-C the amount
found in the receiver is much larger for CF-C. Interstingly,
there is also a clear difference between CF-A and CF-B
when it comes to overall delivery to the skin. This shows
that it is beneficial to distribute more of the water soluble
CF in the ultra-fine dispersed phase with vesicles when a
deeper delivery is aimed at. Importantly, this also shows
that there is an effect of the vesicle carrier as such and that
the penetration improvement does not come from the
lipid matrix functioning as a penetration enhancer alone.
The effect is probably due to an ability of small vesicles to
function as carriers down to a certain depth of the skin.
The characteristics of the vesicles in the ultra-fine dis-
persed phases are shown in Table 1. The somewhat larger
average size obtained for CF-B compared to CF-A is
believed to be process dependent. The close to micron size
for CF-C on the other hand is most likely due to interac-
tions between the adjuvants and the lipid material. The
data show that the presence of the non-ionic adjuvants,
tetraethylene glycol monododecyl ether and polyoxyeth-
ylene 23 glycol monododecyl ether (formulations C),
results in larger vesicle sizes and a somewhat smaller mag-
nitude of zeta-potential. In this context it is important to
realise that inclusion of these surfactants in the vesicle
membrane results in ethylene oxide coils reaching out
from the vesicle surfaces. A reason for the increase in size
may well be that a lateral pressure between ethylene oxide
coils in the membrane (especially on the inside) counter-
acts creation of very small vesicles. The present coils also
reduce mobility of the vesicles but due to the low polymer
density they are not expected to contribute much to the
scattering pattern. This results in a decrease in measured
zeta-potential and has previously been seen for similar
systems [18]. Here it is worth pointing out that the mech-
anism of drug carrier penetration in general is more com-
plex than just a matter of size. This is manifested in
findings that drugs solubilised in micelles have had worse
penetration abilities than corresponding drugs solubilised
in vesicles [19].
Another interesting feature is that the largest amount of
active found in the receiver was for the reference xanthan
gum formulation. Thus the delivered active is not retained
but more easily transferred to the receiver than is the
active when formulated in the lipid matrix gel. The behav-
iour of the reference formulation deserves some com-
ment. The explanation for it being so efficient is probably
that the amount of free water is larger in the reference and
that water is known to work as a penetration enhancer [7].
Moreover the conditions with a large amount of free water
in a gel layer of non-negligable height are close to
occluded conditions. Such conditions have been reported
beneficial for uptake of drugs [20,21]. In contrast, the
slow release from the lipid formulations to the receiver
may in fact indicate a slow release mechanism that is ben-
eficial for many topical treatments since systemic toxicity
is more easily avoided.
In addition, the penetration behaviour of the lipohilic
molecule AO was investigated. The results for the different
formulations are shown in Figure 2. No amount of AO
could be detected in the receiver. This is not surprising
since the solubility in water is low.
Similar to the formulations containing CF the amount in
total skin is highest for the formulation containing the
non-ionic adjuvants. Thus, these adjuvants work well
both for hydrophilic and lipophilic substances. Interest-
Amount of AO detected at different depth of stratum cor- neum Figure 3
Amount of AO detected at different depth of stratum cor-
neum. Errors are standard errors of mean.Lipids in Health and Disease 2006, 5:12 http://www.lipidworld.com/content/5/1/12
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ingly, the distribution of all AO into the vesicle phase
(AO-B) did not have any beneficial effect on the penetra-
tion. This may, in part, be due to the fact that the homog-
enisation was less efficient in the presence of all AO. This
is manifested in that the obtained vesicle size was large
(Table II) and is probably due to that the lipophilic probe
interacts with the membrane in destabilising manner.
Even though one could see a small tendency also for CF
(CF-B) we do not believe that CF interacts with the mem-
brane to any large extent.
Importantly, all lipid matrix formulations were superior
to the reference (vaseline) as far as total delivery of AO to
skin is concerned. In Figure 2 there is no difference in
delivery to stratum corneum. If a closer look is taken at
three different depth of stratum corneum, however, differ-
ences can be seen (Figure 3). From the data it is evident
that for formulations A, B and C the deeper layers contain
more AO than does the reference. In conclusion, the for-
mulation containing adjuvants (C) delivered more than
twice the amount delivered by the reference overall (see
total skin in Fig. 2) which is considered a significant
improvement. If the deeper parts of the skin (total skin
excluding SC) is considered the increase in delivery is over
four times better.
In vivo penetration experiments
The lipid formulations were thus successful concerning
the delivery aspects as determined by the in vitro test. For
the obtained data to be even more sensational they
should be qualitatively applicable to in vivo situations.
Thus, an in vivo model was set up in order to establish the
improved performance over reference for a lipophilic sub-
stance.
The fluorescent microscope image (Figure 4) clearly
shows that the uptake of the fluorescent probe is more
enhanced for the lipid matrix formulation than for the ref-
erence. Remarkably, the effect is seen already 2 hours after
application. It is thus plausible that the in vitro data pre-
sented above correspond to the same trends in vivo even
though exact behaviour is expected to depend on many
factors such as species, age and individual variations of
other kinds.
Conclusion
A new water-based lipid formulation is presented that
provides good penetration properties for both lipophilic
and hydrophilic drugs. The composition of the formula-
tion was chosen with the aim of a small a disturbance of
the skin barrier function as possible. This effect will be
addressed in coming studies.
The formulation showed delivery properties exceeding
that of the references in the pigskin in vitro model. The
effect is largest for lipohilic AO (Acridine orange 10-nonyl
bromide) where all lipid matrix formulations were supe-
rior in amount detected in the skin. The results for the
hydrophilic CF (5(6)-carboxyfluorescein) were also
promising. Especially efficient was the lipid formulation
containing the non-ionic adjuvants tetraethylene glycol
monododecyl ether and polyoxyethylene 23 dodecyl
ether.
The additional in vivo study suggests that the used in vitro
model has qualitative bearing on relevant in vivo situa-
tions.
Abbreviations
CF: 5(6)-carboxyfluorescein, AO: Acridine orange 10-
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